Prelude Therapeutics Incorporated (Nasdaq: PRLD) has released its 2024 financial results and provided an update on its ...

WILMINGTON, Del., March 05, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will ...

Prelude Therapeutics announced promising clinical results for its drug PRT3789, a selective SMARCA2 degrader that has shown safety and anti-tumor activity in patients with SMARCA4-deficient ...

PRT3789 has demonstrated clinical proof-of-concept that selectively degrading SMARCA2 is generally safe and has monotherapy anti-tumor activity ...

D2 Capital Advisors, a Philadelphia-based intermediary, has arranged a $26 million permanent loan for an 80,000-square-foot life sciences building in Wilmington. The building was completed in 2023 as ...

Cash, cash equivalents and marketable securities as of December 31, 2024 were $133.6M. The Company anticipates that its existing cash, cash ...

Prelude Therapeutics Inc (PRLD) stock has reached a new 52-week low, trading at $0.79, as the company faces a challenging market ...

WILMINGTON, Del., March 10, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the ...